CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROPOFOL	ADDITIONAL R	*USP39–NF34*	5575	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTABLE EMULSION	EQUIREMENTS/*USP Reference Standards <11>*						*Supplement to USP40–NF35*	Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl-1,4-benzoquinone.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	*Appendix 3: Types of Biological Safety Cabinets*/Class II	*First Supplement to USP39–NF34*	7721	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5 of *Type A1 (formerly, Type A)*: Change radionucleotides to: radionuclides AND Line 5 of *Type A2 (formerly, Type B3)*: Change radionucleotides to: radionuclides AND Line 5 of *Type B1*: Change radionucleotide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s to: radionuclides AND Line 5 of *Type B2 (total exhaust)*: Change radionucleotide s to: radionuclides
PERINDOPRIL ERBUMINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Perindopril Related Compound A RS: Change (2*S*,3a*S*,7a*S*)- Octahydro-1*H*-indole-2-carboxylic acid hydrochloride. $C_{17}H_{28}N_2O_5 \cdot HCl$ 205.68 to: (2*S*,3a*S*,7a*S*)- Oct

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ahydro -1*H* -indole-2-carboxylic acid. $C_9H_{15}NO_2$ 169.22
CALCIUM GLUCONATE INJECTION	DEFINITION	*USP39–NF34*	2879	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 8: Change It may contain sodium hydroxide added for adjustment of the pH. to: It may contain sodium hydroxide or hydrochloric acid added for adjustment of the pH.
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	OTHER COMPONENTS/*Content of Potassium*	*USP39–NF34*	5465	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 10 of *Analysis*: Change Result = $(C/C_U) \times [M_r/(3 \times A_r)] \times 100$ to: Result = $C \times 100/C_U$ AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 13 of *Analysis*: Change C_U = nominal concentration, based on the *Assay* value, of potassium citrate monohydrate in the *Sample solution* (µg/mL) M_r = molecular weight of potassium citrate monohydrate, 324.41 A_r = atomic weight of potassium, 39.10 to: C_U = concentration of potassium citrate anhydrous ($C_6H_5K_3O_7$) in the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								calculated from the *Assay* value of potassium citrate monohydrate ($C_6H_5K_3O_7 \cdot H_2O$) (µg/mL)
ST. JOHN'S WORT	SPECIFIC TESTS	*USP39–NF34*	6817	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Insert missing test: *Articles of Botanical Origin <561>, Methods of Analysis, Total Ash:* NMT 5.0%
OXYMETAZOLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*/*Table 2*	*First Supplement to USP39–NF34*	8116	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 2 of Column 1: Change Oxymetazoline related compound A to: Oxymetazoline related compound A[a] AND Add footnote a: *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydrox

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y-2,6-dimethylphenyl]acetamide.
ANALYTICAL DATA—INTERPRETATION AND TREATMENT	APPENDIX C: EXAMPLES OF OUTLIER TESTS FOR ANALYTICAL DATA/*Hampel's Rule*	*USP39–NF34*	767	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 13 of Column 4 of *Table 5. Test Results of Re-Applied Hampel's Rule*: Change 0.14 to: 0.15
PARICALCITOL INJECTION	IMPURITIES/*Organic Impurities/ Chromatographic system/ Columns*	*USP39–NF34*	5279	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Guard*: Change 4.6-mm × 7.5-mm; packing L1 to: 4.6-mm × 7.5-mm or 4.6-mm × 10-mm; packing L1
TRAVOPROST OPHTHALMIC SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	6226	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Travoprost Related Compound A RS: Change (5*Z*,13*E*)-(9*S*,11*R*,15*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-9,11,15-Trihydroxy-16-(*m*-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid. to: (5*Z*,13*E*)-(9*S*,11*R*,15*R*)-9,11,15-Trihydroxy-16-(*m*-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid or (*Z*)-7-((1*R*,2*R*,3*R*,5*S*)-3,5-Dihydroxy-2-{(*R*,*E*)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl}cyclopentyl)hept-5-enoic acid.
DANTROLENE	IDENTIFICATIO	*First*	8035	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First*	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM	N/*D.*	*Supplement to USP39–NF34*					*Supplement to USP40–NF35*	*Solution A*: Change tetramethylammonium hydroxide solution to: tetramethylammonium hydroxide TS
PERINDOPRIL ERBUMINE	IM PURITIES/*Organic Impurities*/*Table 2*	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of footnote g: Change ocatahydro to: octahydro
FLUORESCEIN SODIUM	ASSAY/*Procedure*	*USP39–NF34*	3960	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 3 of *Standard stock solution*: Change 1.0 mg/mL of fluorescein sodium in *Diluent* is prepared as follows. to: 1.0 mg/mL of fluorescein sodium is prepared as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								follows.
PROPOFOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5573	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl-1,4-benzoquinone.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	REFERENCES	*First Supplement to USP39–NF34*	7721	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of first reference: Delete http://www.acoem.org/Reproductive_Developmental_Hazard_Management.aspx. AND Line 2 of second reference: Delete http://www.asco.org/advocacy/worker-safety-when-handling-hazardous-drugs-fo

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cus-statement-oncology-societies.
PERINDOPRIL ERBUMINE	CHEMICAL INFORMATION	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 9: Delete (2*S*,3a*S*,7a*S*)-1-{(*S*)-2-[(*R*)-1-Ethoxy-1-oxopentan-2-ylamino]propanoyl}octahydro-1*H*-indole-2-carboxylic acid
CALCIUM GLUCONATE	CHEMICAL INFORMATION	*USP39–NF34*	2877	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5: Change [18016-24-5]. to: [66905-23-5].
PHENYTOIN SODIUM	IDENTIFICATION/*B. Identification Tests—General, Sodium <191>*	*USP39–NF34*	5388	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2: Change tetramethylammonium hydroxide solution, to: tetramethylammonium hydroxide TS,
VITAMIN A ORAL LIQUID PREPARATION	ASSAY/*Vitamin A*	*USP39–NF34*	6374	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 7 of *Analysis*: Change Result = $(r_U/r_S) \times (C/W) \times (V/D)$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								× *U* × (100/*L*) to: Result = (r_U/r_S) × (*C*/*W*) × *D* × *U* × (100/*L*) AND Line 16 of the *Analysis*: Delete *V* = volume of the *Sample solution* (mL)
OXYMETAZOLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8116	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	USP Oxymetazoline Related Compound A RS: Change *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide. $C_{16}H_{26}N_2O_2$ 278.39 to: *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylp

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								henyl]acetamide hydrochloride. $C_{16}H_{26}N_2O_2 \cdot HCl$ 314.85
DESLORATADINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP39–NF34*	8607	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Desloratadine Related Compound B RS: Change 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine. $C_{19}H_{19}ClN_2$ 310.82 to: 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_{19}H_{20}Cl_2N_2$ 347.28
EXTRACTABLES ASSOCIATED WITH PHARMACEUTICAL PACKAGING SYSTEMS	REFERENCES	*USP39–NF34*	1835	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete references 5, 7, 9, and 12.
FLUORESCEIN SODIUM	IMPURITIES/*Organic Impurities*	*USP39–NF34*	3960	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 7 of column 1 of *Table 2*: Change Total impurities to: Total unspecified impurities
HALOPERIDOL DECANOATE	IMPURITIES/*Organic Impurities*/*Table 2*	*USP39–NF34*	4184	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Footnote k: Change 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pipe

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ridin-4-yl decanoate. AND Footnote l: Change 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
RIZATRIPTAN BENZOATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/ Chromatographic procedure*	*USP39–NF34*	5750	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Add *Buffer*: 1.36 g/L of monobasic potassium phosphate. Adjust the pH of the solution with phosphoric acid to 2.5.
TRIHEXYPHENIDYL HYDROCHLORIDE ORAL	*Assay*	*USP39–NF34*	6266	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOLUTION								Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and triethylamine (920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peaks. AND Line 7 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of USP Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
SULINDAC TABLETS	IMPURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8160	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *System suitability*/*Relative*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard deviation: Change NMT 2.0% for any peak to: NMT 2.0% for sulindac, sulindac related compound B, and sulindac related compound C AND Line 3 of *Analysis*: Change Calculate the percentage of the labeled amount of sulindac related compound A, sulindac related compound B, or sulindac related compound C in the portion of Tablets taken: to: Calculate the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								percentage of sulindac related compound B or sulindac related compound C in the portion of Tablets taken: AND Line 8 of *Analysis*: Change r_U = peak response of sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Sample solution* to: r_U = peak response of sulindac related compound B or sulindac related compound C from the *Sample solution* AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 12 of *Analysis*: Change r_S = peak response of sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Standard solution* to: r_S = peak response of sulindac related compound B or sulindac related compound C from the *Standard solution*
FELBAMATE ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	3855	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 4 of *System suitability*: Change [Note—The relative retention times

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								for methylparaben and felbamate are about 0.5 and 1.0, respectively.] to: [Note—The relative retention times for felbamate and methylparaben are about 1.0 and 1.5, respectively.]
GRANISETRON HYDROCHLORIDE TABLETS	*USP Reference standards <11>*	*USP39–NF34*	4155	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to: *N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-az

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								abicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide.
NAPROXEN TABLETS	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP39–NF34*	4993	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Tailing factor*: Change NLT 2.0 to: NMT 2.0
SODIUM NITROPRUSSIDE	*Identification*	*USP39–NF34*	5880	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Identification C*: Change A solution (1 in 4) responds to the flame test for *Sodium* <191>. to: A solution (1 in 4) imparts an intense yellow color to a nonluminous flame.
BISOCTRIZOLE	IMPURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Footnote b of *Table 2*: Change Phenol, 2,2-meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yle nebis[6-(2*H* -benzotriazol-2- yl)-4-(1,1,3,3-tet ramethylbutyl)]. to: Phenol, 2,2?-m
ASSESSMENT OF DRUG PRODUCT LEACHABLES ASSOCIATED WITH PHARMA CEUTICAL PA CKAGING/DELI VERY SYSTEMS	REFERENCES	*USP39–NF34*	1850	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	*H* -benzotriazol-2- yl)-4-(1,1,3,3-tet ramethylbutyl)]. Delete reference 8.
GRANISETRO N HYDROCHL ORIDE	*USP Reference standards <11>*	*USP39–NF34*	4151	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to: (*N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). AND Line 2 of USP Granisetron Related Compound E RS: Change ((1*R*,3*rS*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt). to: ((1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
KETOROLAC TROMETHAMINE INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4468	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 4 of USP Ketorolac Related Compound A RS: Change 358.15 to: 358.39 AND Line 3 of USP Ketorolac Related Compound B RS: Change 227.09 to: 227.26 AND Line 3 of USP Ketorolac Related Compound C RS: Change 225.09 to: 225.24 AND Line 3 of USP Ketorolac Related Compound D:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change 211.1 to: 211.3
SIMETHICONE	ASSAY/ *Procedure/Analysis*	*USP39–NF34*	5843	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Samples*: Change *Standard stock solution*, *Standard solution*, *Sample stock solution*, and *Sample solution* to: *Standard solution* and *Sample solution*
BANABA LEAF DRY EXTRACT	IDENTIFICATION	*USP39–NF34*	6494	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete *Identification A*. AND Line 1 of *Identification B*: Change *B.* to: *A.* AND Line 1 of *Identification C*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C. to: *B.*
OMEGA-3-ACID ETHYL ESTERS CAPSULES	ASSAY/*Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters/Analysis*	*Second Supplement to USP39–NF34*	8755	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 16 of the third equation: Change *L* = label claim of total omega-3-acids ethyl esters (g/Capsule) to: *L* = label claim of total omega-3-acids ethyl esters (mg/Capsule)
FEXOFENADINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP39–NF34*	3895	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 7: Change [138452-21-8]. to: [153439-40-8].
HALCINONIDE CREAM	IM PURITIES/*Organic Impurities/ Chromatographic system*	*USP39–NF34*	4176	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Column*: Change 1.8-µm packing L1 to: 1.7-µm packing L1
NAPROXEN TABLETS	IM PUR	*USP39–NF34*	4993	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to*	Line 6 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities*						*USP40–NF35*	Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
TRIHEXYPHENIDYL HYDROCHLORIDE EXTENDED-RELEASE CAPSULES	*Assay*	*USP39–NF34*	6265	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and triethylamine (920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								System Suitability under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: Separately inject equal volumes (about 10 µL) of the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparation and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. AND Line 6 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of USP Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obtained from the *Assay preparation* and the *Standard preparation*, respectively.
BISOCTRIZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Bisoctrizole Resolution Mixture RS: Change A mixture of approximately 1.5% of bisoctrizole isomer [phenol, 2,2-methylenebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole. to: A mixture of approximately 1.5% of bisoctrizole isomer [phenol, 2,2?-methylene bis[6-(2*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole.
ORALLY INHALED AND NASAL DRUG PRODUCTS	REFERENCES	*USP39–NF34*	1862	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete reference 3.
GRANISETRON HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	4153	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to: *N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide.
LOVASTATIN	*USP Reference standards <11>*	*USP39–NF34*	4631	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to*	Line 2 of USP Lovastatin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							USP40–NF35	Related Compound A RS: Change [Dihydro-lovastatin][butanoic acid, 2-methyl-, 1,2,3,4,4a,7,8,8a-octahydro-3,7-dimethyl-8-[2(tetrahydro-4-hydrox y-6-ox o-2*H* -pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1*S*-[1?(*R* *), 3?,7? ,8?(2*S**,4*S* *),-8??]]]-. to: (1*S*,3*S*,4a*R*,7*S*,8*S*,8a*S*)-8-{2-[(2*R*,4*R*)-4-hydroxy-6-ox ot etra hydro-2*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyran-2-yl]ethyl }-3,7-dimethyl-1 ,2,3,4,4a,7,8,8a -octahydronapht halen-1-yl (*S*)-2-methylbutan oate.
SIMVASTATIN TABLETS	IM PUR ITIES/*Organic Impuri ties/Analysis*	*USP39–NF34*	5848	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND Delete the variable definitions for M_{r1} and M_{r2}.
FUMARIC ACID	SPECIFIC TESTS/*Water Determination, Method I <921>*	*USP39–NF34*	7309	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1: Change 0.5% to: NMT 0.5%
NAPROXEN SODIUM TABLETS	IM PUR ITIES/*Organic Impurities*	*Second Supplement to USP39–NF34*	Online	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 6 of *Analysis*: Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = (*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/r_S$) × (C_S/C_U) × 100
BACITRACIN ZINC	IMPURITIES	*USP39–NF34*	2674	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Delete the *Residue on Ignition <281>* test.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- …
- Next page Next ›
- Last page Last »